These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 11681781)

  • 21. [Cost effectiveness of the use of spironolactone in the treatment of chronic heart failure].
    Soto Alvarez J; González Vilchez F
    An Med Interna; 2001 Aug; 18(8):421-5. PubMed ID: 11589080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The significance of aldosterone in chronic heart failure: the RALES study].
    Simko F; Bada V; Simková M; Simko J; Kovács L; Hulín I
    Vnitr Lek; 2002 Aug; 48(8):767-72. PubMed ID: 12425209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure].
    Fuster D; Frey FJ; Ferrari P
    Praxis (Bern 1994); 2000 Dec; 89(49):2073-6. PubMed ID: 11190849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure.
    Lenzen MJ; Boersma E; Reimer WJ; Balk AH; Komajda M; Swedberg K; Follath F; Jimenez-Navarro M; Simoons ML; Cleland JG
    Eur Heart J; 2005 Dec; 26(24):2706-13. PubMed ID: 16183692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Value of diuretics and aldosterone antagonists in the treatment of heart failure].
    Schwinger RH
    Dtsch Med Wochenschr; 1999 Sep; 124 Suppl 2():S40-7. PubMed ID: 10535046
    [No Abstract]   [Full Text] [Related]  

  • 26. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
    Tamirisa KP; Aaronson KD; Koelling TM
    Am Heart J; 2004 Dec; 148(6):971-8. PubMed ID: 15632880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Chronic heart insufficiency should be treated also with spironolactone].
    Kjeldsen KP; Nørgaard A; Thygesen K
    Ugeskr Laeger; 1999 Sep; 161(37):5132. PubMed ID: 10523942
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aldosterone and spironolactone in heart failure.
    Weber KT
    N Engl J Med; 1999 Sep; 341(10):753-5. PubMed ID: 10471464
    [No Abstract]   [Full Text] [Related]  

  • 30. New hope for heart failure.
    DeMaria A
    Health News; 1999 Sep; 5(11):1-2. PubMed ID: 10513252
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of heart failure in infants and children.
    Clark BJ
    Heart Dis; 2000; 2(5):354-61. PubMed ID: 11728282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia.
    Cruz CS; Cruz LS; Domingues GS; Souza CA
    Expert Opin Drug Saf; 2005 Jul; 4(4):677-88. PubMed ID: 16011447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spironolactone for heart failure: a worthy addition to therapy.
    Rittenhouse SK
    Adv Nurse Pract; 2001 Jan; 9(1):34-6, 39. PubMed ID: 12416036
    [No Abstract]   [Full Text] [Related]  

  • 34. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aldosterone antagonists in congestive heart failure.
    Soberman J; Chafin CC; Weber KT
    Curr Opin Investig Drugs; 2002 Jul; 3(7):1024-8. PubMed ID: 12186262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of the addition of a low dose of spironolactone on brain natriuretic peptide plasma level and cardiopulmonary function in patients with moderate congestive heart failure.
    Feola M; Menardi E; Ribichini F; Vado A; Deorsola A; Ferrero V; Visconti G; Milanese U; Uslenghi E
    Med Sci Monit; 2003 Aug; 9(8):CR341-5. PubMed ID: 12942029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High prevalence of microalbuminuria in chronic heart failure patients.
    van de Wal RM; Asselbergs FW; Plokker HW; Smilde TD; Lok D; van Veldhuisen DJ; van Gilst WH; Voors AA
    J Card Fail; 2005 Oct; 11(8):602-6. PubMed ID: 16230263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adherence to guidelines for patients hospitalized with heart failure: a nationwide survey.
    Jotkowitz AB; Porath A; Shotan A; Mittelman M; Grossman E; Zimlichman R; Lewis BS; Caspi A; Gottlieb S; Garty M;
    Isr Med Assoc J; 2006 Dec; 8(12):875-9. PubMed ID: 17214110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spironolactone in severe heart failure: enhances efficacy of diuretic + ACE inhibitor combinations.
    Prescrire Int; 2000 Oct; 9(49):158-9. PubMed ID: 11603418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Just the berries. Management of heart failure.
    Ruggles L
    Can Fam Physician; 2001 Mar; 47():499-501. PubMed ID: 11281082
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.